Duration of Chemotherapy Prior to Chemoradiation Affects Survival Outcomes for Resected Stage I-II or Unresected Stage III Pancreatic Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Jun 12

PMID 31183965

Citations 2

Authors

Sung J Ma

Austin J Iovoli

Gregory M Hermann

Kavitha M Prezzano

Anurag K Singh

Affiliations

Soon will be listed here.

Abstract

Background: For resected early stage pancreatic cancer, RTOG 9704 evaluated the outcome of 3 weeks of postoperative chemotherapy (C) followed by chemoradiation (CRT) and further C. For unresectable locally advanced pancreatic cancer, a recent literature review of prospective studies showed that the duration of induction C prior to CRT can impact survival. However, the ideal duration of C prior to CRT remains unclear for these patient cohorts. This National Cancer Database (NCDB) study was performed to compare the outcome of various durations of C prior to CRT.

Methods: The NCDB was queried for resected primary stage I-II, cT1-3N0-1M0, and unresected stage III, cT4N0-1M0 pancreatic adenocarcinoma treated with C + CRT (2004-2015). Cohorts I-II and III included stage I-II and stage III cases, respectively. Patients were stratified by short (short C) and long duration (long C) of chemotherapy based on their median durations. Baseline patient, tumor, and treatment characteristics were examined. The primary endpoint was overall survival (OS). Kaplan-Meier analysis, multivariable Cox proportional hazards method, and propensity score matching were used.

Results: Among 1577 patients, cohort I-II had 839 patients and cohort III had 738 patients. The longer duration of chemotherapy prior to CRT showed improved OS in the multivariate analysis in both cohort I-II (hazards ratio [HR] 0.72, P < 0.001) and cohort III (HR 0.83, P = 0.03). Using 1:1 propensity score matching, 610 patients for cohort I-II and 542 patients for cohort III were matched. After matching, long C remained statistically significant for improved OS compared with short C in both cohort I-II (median OS 26.1 vs 21.9 months; P = 0.003) and cohort III (median OS 16.7 vs 14.2; P = 0.02).

Conclusion: Our NCDB study using propensity score-matched analysis showed a survival benefit for using the longer duration of chemotherapy compared to the shorter duration for both resected stage I-II and unresected stage III pancreatic cancer.

Citing Articles

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications.

Deig C, Sutton T, Beneville B, Trone K, Stratton A, Gunesch A Cancers (Basel). 2022; 14(3).

PMID: 35158877 PMC: 8833799. DOI: 10.3390/cancers14030609.

Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.

Ma S, Iovoli A, Hermann G, Prezzano K, Singh A Cancer Med. 2019; 8(9):4110-4123.

PMID: 31183965 PMC: 6675727. DOI: 10.1002/cam4.2326.

References

Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

Neoptolemos J, Stocken D, Dunn J, Almond J, Beger H, Pederzoli P . Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001; 234(6):758-68. PMC: 1422135. DOI: 10.1097/00000658-200112000-00007. View

Simons J, Ng S, McDade T, Zhou Z, Earle C, Tseng J . Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer. 2010; 116(7):1681-90. DOI: 10.1002/cncr.24918. View

Yovino S, Maidment 3rd B, Herman J, Pandya N, Goloubeva O, Wolfgang C . Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys. 2012; 83(3):916-20. PMC: 3556989. DOI: 10.1016/j.ijrobp.2011.08.026. View

Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F . Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007; 25(3):326-31. DOI: 10.1200/JCO.2006.07.5663. View

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I . Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer. 2017; 123(19):3816-3824. DOI: 10.1002/cncr.30780. View

Chang H, Lin Y, Wang H, Chiu Y, Chang M, Hsu C . Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study. Int J Radiat Oncol Biol Phys. 2011; 81(5):e749-57. DOI: 10.1016/j.ijrobp.2010.10.034. View

Regine W, Winter K, Abrams R, Safran H, Hoffman J, Konski A . Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011; 18(5):1319-26. PMC: 3548408. DOI: 10.1245/s10434-011-1630-6. View

10.

Chang J, Chiu Y, Yu J, Chen L, Chang H . The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Res Treat. 2017; 50(2):562-574. PMC: 5912129. DOI: 10.4143/crt.2017.105. View

11.

Barraclough H, Govindan R . Biostatistics primer: what a clinician ought to know: subgroup analyses. J Thorac Oncol. 2010; 5(5):741-6. DOI: 10.1097/JTO.0b013e3181d9009e. View

12.

Van Laethem J, Hammel P, Mornex F, Azria D, van Tienhoven G, Vergauwe P . Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010; 28(29):4450-6. PMC: 2988636. DOI: 10.1200/JCO.2010.30.3446. View

13.

Zhong J, Patel K, Switchenko J, Cassidy R, Hall W, Gillespie T . Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017; 123(18):3486-3493. PMC: 5589506. DOI: 10.1002/cncr.30706. View

14.

Ma S, Iovoli A, Hermann G, Prezzano K, Singh A . Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer. Cancer Med. 2019; 8(9):4110-4123. PMC: 6675727. DOI: 10.1002/cam4.2326. View

15.

Krishnan S, Chadha A, Suh Y, Chen H, Rao A, Das P . Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016; 94(4):755-65. PMC: 4792191. DOI: 10.1016/j.ijrobp.2015.12.003. View

16.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

17.

Faisal F, Tsai H, Blackford A, Olino K, Xia C, De Jesus-Acosta A . Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2013; 39(1):18-26. PMC: 4061284. DOI: 10.1097/COC.0000000000000022. View

18.

Bilimoria K, Stewart A, Winchester D, Ko C . The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008; 15(3):683-90. PMC: 2234447. DOI: 10.1245/s10434-007-9747-3. View

19.

Krishnan S, Rana V, Janjan N, Varadhachary G, Abbruzzese J, Das P . Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007; 110(1):47-55. DOI: 10.1002/cncr.22735. View